Frequency of Protease and Reverse Transcriptase Drug Resistance Mutations in Naïve HIV-Infected Patients

Archives of Medical Research

Volumn 37, Issue 8, 2006, Pages 1022-1027

  Valle Bahena, Olivia M ^a,c   Ramos Jiménez, Javier ^b   Ortiz López, Rocío ^c   Revol, Agnès ^c   Lugo Trampe, Ángel ^c   Barrera Saldaña, Hugo A ^c   Rojas Martínez, Augusto ^c  

^a UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MÉXICO   (Mexico)

^b HOSPITAL UNIVERSITARIO DR JOSÉ ELEUTERIO GONZÁLEZ   (Mexico)

^c Medicina UANL   (Mexico)

Author keywords

Antiretroviral therapy; HIV drug resistance; Protease inhibitors; Resistance mutations; Reverse transcriptase inhibitors

Indexed keywords

ANTIRETROVIRUS AGENT; ENZYME INHIBITOR; NUCLEOSIDE RETROTRANSCRIPTASE INHIBITOR; PROTEINASE; RNA; RNA DIRECTED DNA POLYMERASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MALE; MEXICO; MUTATION; NUCLEOTIDE SEQUENCE; PLASMA;

EID: 33749637541     PISSN: 01884409     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.arcmed.2006.05.014     Document Type: Article

References (25)

1. Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338 (1998) 853-860
2. Murphy E.L., Collier A.C., Kalish L.A., Assmann S.F., Para M.F., Flanigan T.P., et al. and the Viral Activation Transfusion Study Investigators. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med 135 (2001) 17-26
3. Piot P., Bartos M., Ghys P.D., Walker N., and Schwartlander B. The global impact of HIV/AIDS. Nature 410 (2001) 968-973
4. Hecht F.M., Grant R.M., Petropoulos C.J., Dillon B., Chesney M.A., Tian H., et al. Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 339 (1998) 307-311
5. Yerly S., Kaiser L., Race E., Bru J.P., Clavel F., and Perrin L. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 354 (1999) 729-733
6. Frenkel L.M., Wagner II L.E., Demeter L.M., Dewhurst S., Coombs R.W., Murante B.L., et al. Effects of zidovudine use during pregnancy on resistance and vertical transmission of human immunodeficiency virus type 1. Clin Infect Dis 20 (1995) 1321-1326
7. Wensing A.M., van de Vijver D.A., Angarano G., Asjo B., Balotta C., Boeri E., et al. SPREAD Programme. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis 192 (2005) 958-966
8. Novak R.M., Chen L., MacArthur R.D., Baxter J.D., Huppler Hullsiek K., Peng G., et al. Terry Beirn Community Programs for Clinical Research on AIDS 058 Study Team. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naive patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 40 (2005) 468-474
9. Vazquez de Parga E., Rakhmanova A., Perez-Alvarez L., Vinogradova A., Delgado E., Thomson M.M., et al. Analysis of drug resistance-associated mutations in treatment-naive individuals infected with different genetic forms of HIV-1 circulating in countries of the former Soviet Union. J Med Virol 77 (2005) 337-344
10. Weinstock H.S., Zaidi I., Heneine W., Bennett D., Garcia-Lerma J.G., Douglas Jr. J.M., et al. The epidemiology of antiretroviral drug resistance among drug-naive HIV-1-infected persons in 10 US cities. J Infect Dis 189 (2004) 2174-2180
11. Little S.J., Holte S., Routy J.P., Daar E.S., Markowitz M., Collier A.C., et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 347 (2002) 385-394
12. Escoto-Delgadillo M., Vazquez-Valls E., Ramirez-Rodriguez M., Corona-Nakamura A., Amaya-Tapia G., Quintero-Perez N., et al. Drug-resistance mutations in antiretroviral-naive patients with established HIV-1 infection in Mexico. HIV Med 6 (2005) 403-409
13. Johnson V.A., Brun-Vezinet F., Clotet B., Conway B., Kuritzkes D.R., Pillay D., et al. Update of the drug resistance mutations in HIV-1: Fall 2005. Top HIV Med 13 (2005) 125-131
14. In: Leitner T., Foley B., Hahn B., Marx P., McCutchan F., Mellors J., et al. (Eds). HIV sequence compendium 2005 (2005), Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM
15. Kumar S., Tamura K., Jakobsen I.B., and Nei M. MEGA2: molecular evolutionary genetics analysis software. Bioinformatics 17 (2001) 1244-1245
16. El SIDA en cifras 2005. http://www.salud.gob.mx/conasida/. December 31, 2005.
17. Centers for Disease Control and Prevention. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. http://www.aidsinfo.nih.gov/guidelines. October 29, 2004.
18. Perez E.E., Rose S.L., Peyser B., Lamers S.L., Burkhardt B., Dunn B.M., et al. Human immunodeficiency virus type 1 protease genotype predicts immune and viral responses to combination therapy with protease inhibitors (PIs) in PI-naive patients. J Infect Dis 183 (2001) 579-588
19. Lanier E.R., Ait-Khaled M., Scott J., Stone C., Melby T., Sturge G., et al. Antiviral efficacy of abacavir in antiretroviral therapy-experienced adults harbouring HIV-1 with specific patterns of resistance to nucleoside reverse transcriptase inhibitors. Antivir Ther 9 (2004) 37-45
20. Kijak G.H., Pampuro S.E., Avila M.M., Zala C., Cahn P., Wainberg M.A., et al. Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina. Antivir Ther 6 (2001) 71-77
21. Brindeiro R.M., Diaz R.S., Sabino E.C., Morgado M.G., Pires I.L., Brigido L., et al. Brazilian Network for Drug Resistance Surveillance. Brazilian Network for HIV Drug Resistance Surveillance (HIV-BResNet): a survey of chronically infected individuals. AIDS 17 (2003) 1063-1069
22. Barreto C.C., Nishyia A., Araujo L.V., Ferreira J.E., Busch M.P., and Sabino E.C. Trends in antiretroviral drug resistance and clade distributions among HIV-infected blood donors in Sao Paulo, Brazil. J Acquir Immune Defic Syndr 41 (2006) 338-341
23. UK Group on Transmitted HIV Drug Resistance. Time trends in primary resistance to HIV drugs in the United Kingdom: multicentre observational study. BMJ 331 (2005) 1368
24. Fox J.M., Fidler S., and Weber J. Resistance to HIV drugs in UK may be lower in some areas. BMJ 21 (2006) 179-180
25. McClernon D., Danehower S., Thompson M., Fischl M., Hessenthaler S., St. Clair M., et al. Low Prevalence of Key Resistance Mutations in Under-Represented and Incarcerated, Antiretroviral Therapy Naïve, HIV-1 Infected Adults in North America. The 1st IAS Conference on HIV Pathogenesis and Treatment. Buenos Aires (2001)